Fenpiverinium

Fenpiverinium

SCHEMBL1650132

C[N+]1(CCC(C(N)=O)(c2ccccc2)c2ccccc2)CCCCC1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 11/20 0.55
CHRM2 P08172 7/20 0.55
CHRM1 P11229 3/20 0.55
CHRM4 P08173 2/20 0.55
CHRM5 P08912 2/20 0.55
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
LMNA P02545 1/20 0.48
CYP2D6 P10635 1/20 0.48
KCNH2 Q12809 1/20 0.48
KDM4E B2RXH2 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
APOBEC3A P31941 3/20 0.42
APOBEC3G Q9HC16 3/20 0.42
HTT P42858 1/20 0.42
MAPT P10636 1/20 0.40
PABPC1 P11940 2/20 0.39
SLC22A2 O15244 1/20 0.39
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Buzepide SCHEMBL3498775 0.99 CHRM3 (0.57) CHRM3CHRM2CHRM1CHRM4CHRM5
Fenpiverinium SCHEMBL23654 0.99 CHRM3 (0.53) CHRM3CHRM2CHRM1CHRM4CHRM5
Fenpiverinium SCHEMBL28086315 0.86 OPRM1 (0.43) CHRM3CHRM2CHRM1CHRM4CHRM5
Iodide SCHEMBL29558329 0.76 CHRM2 (0.83) CHRM3CHRM2CHRM1CHRM4CHRM5
SCHEMBL9295790 0.73 CHRM3 (0.59) CHRM3CHRM2CHRM1KMT2ALMNA
SCHEMBL10524246 0.71 CHRM3 (0.57) CHRM3CHRM2CHRM1KMT2ALMNA
SCHEMBL219257 0.71 CHRM2 (0.60) CHRM3CHRM2CHRM1CHRM4CHRM5
Fenpipramide SCHEMBL149504 0.71 CHRM2 (0.60) CHRM3CHRM2CHRM1CHRM4CHRM5
Fenpipramide SCHEMBL11716116 0.70 OPRM1 (0.56) CHRM3CHRM2CHRM1CHRM4CHRM5
Tricyclamol SCHEMBL30573196 0.70 CHRM2 (0.58) CHRM3CHRM2CHRM1CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026100654-A1 NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD 株式会社インファーマシア 2026-05-15 WO claimed
EP-4154879-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS KOREA INST SCI & TECH (KR) 2025-09-10 EP claimed
EP-4154879-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS Korea Institute of Science and Technology (KR) 2023-03-29 EP claimed
US-11065205-B2 Immediate/delayed drug delivery DRUG DELIVERY INTERNATIONAL LIMITED (GB) 2021-07-20 US claimed
US-10689370-B2 Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator AUSPEX PHARMACEUTICALS, INC. (US) 2020-06-23 US claimed
US-20190125679-A1 IMMEDIATE/DELAYED DRUG DELIVERY UNIVERSITY OF STRATHCLYDE (GB) 2019-05-02 US claimed
EP-3373943-A1 CONTROL OF CELLULAR REDOX LEVELS Mckenna, Elizabeth (US) 2018-09-19 EP claimed
EP-2956450-B1 HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE UNIV MUENCHEN TECH (DE) 2018-07-25 EP claimed
EP-2542228-B1 PULSATILE DRUG RELEASE UNIV STRATHCLYDE (GB) 2017-11-29 EP claimed
EP-2542227-B1 IMMEDIATE/DELAYED DRUG DELIVERY UNIV STRATHCLYDE (GB) 2017-11-22 EP claimed
WO-2009018169-A1 SUBSTITUTED CYCLOHEXANOLS AUSPEX PHARMACEUTICALS, INC. (US) 2009-02-05 WO claimed
US-20090028873-A1 SUBSTITUTED CYCLOHEXANOLS AUSPEX PHARMACEUTICALS, INC. (US) 2009-01-29 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5876751-A MIXTURE OF PITOFENONE HYDROCHLORIDE AND FENPIVERINIUM BROMIDE PANACEA BIOTEC LIMITED (IN) 1999-03-02 US claimed
EP-0193056-B1 COMBINATION OF FLUPIRTIN WITH SPASMOLYTICS HAVING AN ANTICHOLINERGIC EFFECT ASTA Pharma Aktiengesellschaft (DE) 1989-06-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689370-B2 Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator CFTR, CLCN2, TMEM120A CHRM3 748/4885CHRM2 1950/4885CHRM1 3497/4885
US-20090028873-A1 SUBSTITUTED CYCLOHEXANOLS OPRM1, OPRD1, OPRK1 CHRM3 94/4885CHRM2 103/4885CHRM1 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.